Professor Mark Middleton appointed to Physiomics SAB

Physiomics plc is pleased to announce that it has appointed Professor Mark Middleton to its Scientific Advisory Board. Professor Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology of the University of Oxford. He is an eminent clinician with highly relevant clinical experience.

Mark is the Lead Cancer Clinician for the Oxford University Hospitals NHS Trust and deputy director of the Cancer Research UK Oxford Centre. He directs the EPCTU and the Cancer Theme of the NIHR Biomedical Research Centre. Mark studied medicine at Cambridge and Oxford and trained in medical oncology at the Christie Hospital. He is a member of the International Melanoma Working Group and of the NCRI Melanoma Clinical Studies Group. Mark leads several clinical trials in the national portfolio, with an emphasis on early phase trials of new drugs or drug combinations.

The directors believe that Mark’s experience as a clinical oncologist will be invaluable, particularly as the Company seeks to access the stratified and personalised medicine market.

Dr Mark Chadwick, CEO of Physiomics, commented: “We are delighted to welcome Professor Middleton to our SAB. His undoubted knowledge and expertise will be invaluable to Physiomics as we look to increase the number of clinical projects we undertake and also seek to address the emerging market of stratified and personalised medicine for cancer treatment.”